Concepts (131)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiopharmaceuticals | 7 | 2019 | 1301 | 0.720 |
Why?
|
| Alpha Particles | 1 | 2019 | 26 | 0.710 |
Why?
|
| Fluorodeoxyglucose F18 | 6 | 2019 | 1226 | 0.690 |
Why?
|
| Musculoskeletal Diseases | 2 | 2009 | 81 | 0.660 |
Why?
|
| Radium | 1 | 2019 | 93 | 0.660 |
Why?
|
| Neuroendocrine Tumors | 4 | 2024 | 634 | 0.500 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2019 | 840 | 0.490 |
Why?
|
| Positron Emission Tomography Computed Tomography | 4 | 2021 | 833 | 0.460 |
Why?
|
| Radioisotopes | 2 | 2024 | 177 | 0.390 |
Why?
|
| Chemoradiotherapy | 1 | 2019 | 1946 | 0.380 |
Why?
|
| Octreotide | 3 | 2023 | 118 | 0.350 |
Why?
|
| Positron-Emission Tomography | 4 | 2016 | 2173 | 0.340 |
Why?
|
| Bone Neoplasms | 2 | 2019 | 2576 | 0.340 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2016 | 7551 | 0.330 |
Why?
|
| Tomography, Emission-Computed | 1 | 2009 | 310 | 0.320 |
Why?
|
| Organometallic Compounds | 2 | 2018 | 191 | 0.290 |
Why?
|
| Lutetium | 1 | 2024 | 6 | 0.250 |
Why?
|
| Intestinal Neoplasms | 1 | 2023 | 189 | 0.200 |
Why?
|
| Cyclobutanes | 1 | 2021 | 36 | 0.200 |
Why?
|
| Carboxylic Acids | 1 | 2021 | 57 | 0.190 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2021 | 109 | 0.180 |
Why?
|
| Denosumab | 1 | 2019 | 68 | 0.170 |
Why?
|
| Incidental Findings | 1 | 2021 | 272 | 0.170 |
Why?
|
| Injections, Intravenous | 1 | 2019 | 573 | 0.170 |
Why?
|
| Still's Disease, Adult-Onset | 1 | 2017 | 3 | 0.160 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2024 | 716 | 0.150 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2020 | 406 | 0.150 |
Why?
|
| Insulinoma | 1 | 2017 | 55 | 0.150 |
Why?
|
| Sarcoidosis | 1 | 2018 | 112 | 0.150 |
Why?
|
| Granuloma | 1 | 2018 | 154 | 0.140 |
Why?
|
| Gastroplasty | 1 | 2016 | 22 | 0.140 |
Why?
|
| Foreign-Body Reaction | 1 | 2016 | 27 | 0.140 |
Why?
|
| Bone and Bones | 1 | 2019 | 619 | 0.140 |
Why?
|
| Tamoxifen | 1 | 2019 | 876 | 0.130 |
Why?
|
| Breast Neoplasms | 1 | 2019 | 15694 | 0.130 |
Why?
|
| Surgical Mesh | 1 | 2016 | 209 | 0.120 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2020 | 1146 | 0.120 |
Why?
|
| Receptors, Progesterone | 1 | 2019 | 1392 | 0.120 |
Why?
|
| Ipilimumab | 1 | 2018 | 710 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 2 | 2023 | 5061 | 0.110 |
Why?
|
| Breast | 1 | 2019 | 1344 | 0.110 |
Why?
|
| Preoperative Care | 1 | 2019 | 1529 | 0.110 |
Why?
|
| Lymphatic Metastasis | 2 | 2019 | 4844 | 0.110 |
Why?
|
| Peritoneal Neoplasms | 1 | 2019 | 821 | 0.110 |
Why?
|
| Receptors, Estrogen | 1 | 2019 | 2086 | 0.110 |
Why?
|
| Balloon Occlusion | 1 | 2012 | 49 | 0.100 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2017 | 600 | 0.100 |
Why?
|
| Yttrium Radioisotopes | 1 | 2012 | 178 | 0.100 |
Why?
|
| Whole Body Imaging | 1 | 2011 | 114 | 0.100 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2020 | 1664 | 0.090 |
Why?
|
| Endometrial Neoplasms | 1 | 2019 | 1341 | 0.090 |
Why?
|
| Aged | 11 | 2021 | 70117 | 0.090 |
Why?
|
| Liver Diseases | 1 | 2015 | 574 | 0.090 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 1249 | 0.080 |
Why?
|
| Radiographic Image Enhancement | 1 | 2011 | 402 | 0.080 |
Why?
|
| Humans | 20 | 2024 | 261506 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 3251 | 0.070 |
Why?
|
| Middle Aged | 9 | 2020 | 86204 | 0.070 |
Why?
|
| Radiation Dosage | 1 | 2011 | 1014 | 0.070 |
Why?
|
| Adult | 8 | 2020 | 77950 | 0.070 |
Why?
|
| Hodgkin Disease | 1 | 2014 | 1429 | 0.060 |
Why?
|
| Quality of Life | 1 | 2018 | 4532 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 2021 | 5767 | 0.060 |
Why?
|
| Receptors, Peptide | 1 | 2024 | 86 | 0.060 |
Why?
|
| Female | 11 | 2020 | 141928 | 0.060 |
Why?
|
| Biopsy | 2 | 2024 | 3443 | 0.060 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2023 | 211 | 0.060 |
Why?
|
| Skin Neoplasms | 1 | 2018 | 4654 | 0.050 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 5112 | 0.050 |
Why?
|
| Radiation Injuries | 1 | 2008 | 1411 | 0.050 |
Why?
|
| Melanoma | 1 | 2018 | 5317 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2019 | 2292 | 0.050 |
Why?
|
| Radionuclide Imaging | 2 | 2012 | 660 | 0.050 |
Why?
|
| Biological Transport | 1 | 2021 | 597 | 0.040 |
Why?
|
| Salpingo-oophorectomy | 1 | 2019 | 50 | 0.040 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2020 | 113 | 0.040 |
Why?
|
| Consensus | 1 | 2023 | 978 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2015 | 7702 | 0.040 |
Why?
|
| False Negative Reactions | 1 | 2019 | 275 | 0.040 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2020 | 224 | 0.040 |
Why?
|
| Male | 9 | 2021 | 123000 | 0.040 |
Why?
|
| Contrast Media | 2 | 2017 | 1472 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 470 | 0.040 |
Why?
|
| Sentinel Lymph Node | 1 | 2019 | 216 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2017 | 208 | 0.040 |
Why?
|
| Hysterectomy | 1 | 2019 | 611 | 0.030 |
Why?
|
| Endometrium | 1 | 2019 | 470 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 6009 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2012 | 4557 | 0.030 |
Why?
|
| Nausea | 1 | 2017 | 525 | 0.030 |
Why?
|
| Prospective Studies | 3 | 2019 | 12873 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 4971 | 0.030 |
Why?
|
| Image-Guided Biopsy | 1 | 2017 | 327 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2017 | 1382 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 14289 | 0.030 |
Why?
|
| Obesity, Morbid | 1 | 2016 | 224 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2023 | 3719 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 1586 | 0.030 |
Why?
|
| Rituximab | 1 | 2017 | 1528 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 29902 | 0.030 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2019 | 1415 | 0.030 |
Why?
|
| Transcriptome | 1 | 2020 | 1859 | 0.030 |
Why?
|
| Microspheres | 1 | 2012 | 210 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2011 | 91 | 0.020 |
Why?
|
| Multimodal Imaging | 1 | 2015 | 550 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 3472 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 4892 | 0.020 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2011 | 341 | 0.020 |
Why?
|
| Lymphoma | 1 | 2017 | 1467 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2018 | 32848 | 0.020 |
Why?
|
| Linear Models | 1 | 2011 | 1085 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2008 | 305 | 0.020 |
Why?
|
| Perfusion | 1 | 2008 | 293 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 6207 | 0.020 |
Why?
|
| United States | 1 | 2023 | 15433 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 5687 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2008 | 11538 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 4744 | 0.020 |
Why?
|
| Phantoms, Imaging | 1 | 2011 | 1271 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 4988 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 10001 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2008 | 592 | 0.020 |
Why?
|
| Prognosis | 2 | 2014 | 21713 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2008 | 3842 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2015 | 37905 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 10035 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 8865 | 0.010 |
Why?
|
| Young Adult | 1 | 2014 | 21445 | 0.010 |
Why?
|
| Adolescent | 1 | 2014 | 31252 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 15862 | 0.010 |
Why?
|
| Risk Factors | 1 | 2008 | 17523 | 0.010 |
Why?
|